A hypothesis to phenotype COPD exacerbations by aetiology
暂无分享,去创建一个
[1] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[2] Edwin K Silverman,et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.
[3] R. Pandey,et al. Prevalence of viral infection detected by PCR and RT‐PCR in patients with acute exacerbation of COPD: A systematic review , 2010, Respirology.
[4] T. Omachi,et al. Influence of anxiety on health outcomes in COPD , 2010, Thorax.
[5] W. Boersma,et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.
[6] D. Caillaud,et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses , 2010, European Respiratory Journal.
[7] M. Weatherall,et al. Distinct clinical phenotypes of airways disease defined by cluster analysis , 2009, European Respiratory Journal.
[8] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[9] G. Donaldson,et al. Relationship between depression and exacerbations in COPD , 2008, European Respiratory Journal.
[10] Clifford W Colwell,et al. Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .
[11] T. Murphy,et al. Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[12] J. Bourbeau,et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. , 2008, American journal of respiratory and critical care medicine.
[13] B. Caldwell,et al. External validity of randomized controlled trials in COPD. , 2007, Respiratory medicine.
[14] B. Celli,et al. Exacerbations of chronic obstructive pulmonary disease , 2007, European Respiratory Journal.
[15] G. Donaldson,et al. Inflammatory changes, recovery and recurrence at COPD exacerbation , 2007, European Respiratory Journal.
[16] J. Wedzicha,et al. What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines , 2007, Thorax.
[17] Richard Beasley,et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? , 2006, Thorax.
[18] J. Cornuz,et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease? , 2006, Thorax.
[19] M. Christ-Crain,et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. , 2007, Chest.
[20] J. Soriano,et al. Dynamic hyperinflation and pulmonary inflammation: a potentially relevant relationship? , 2006, European Respiratory Review.
[21] John R Hurst,et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[22] T. Honda,et al. Characteristics of COPD phenotypes classified according to the findings of HRCT. , 2006, Respiratory medicine.
[23] S. Johnston,et al. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study , 2006, Respiratory research.
[24] S. Johnston,et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.
[25] S. Sethi,et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[26] C. Marquette,et al. Pulmonary Embolism in Patients with Unexplained Exacerbation of Chronic Obstructive Pulmonary Disease: Prevalence and Risk Factors , 2006, Annals of Internal Medicine.
[27] C. Schindler,et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. , 2006, American heart journal.
[28] J. Wedzicha,et al. Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD , 2006, Chest.
[29] G. Donaldson,et al. COPD exacerbations · 1: Epidemiology , 2006, Thorax.
[30] S. Pallesen,et al. Psychological characteristics of patients with chronic obstructive pulmonary disease: a review. , 2005, Journal of psychosomatic research.
[31] I. Pavord,et al. Multi‐dimensional phenotyping: towards a new taxonomy for airway disease , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[32] M. Martínez-García,et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease , 2005, Thorax.
[33] C. Jenkins,et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.
[34] Joan B Soriano,et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. , 2003, Chest.
[35] J. Hollander,et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[36] A. Gillissen,et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study , 2003, Thorax.
[37] T. Seemungal,et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.
[38] D. Postma,et al. Chronic obstructive pulmonary disease. , 2002, Clinical evidence.
[39] E. Rönmark,et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). , 2002, Respiratory medicine.
[40] S. Quintana,et al. Mortality after hospitalization for COPD. , 2002, Chest.
[41] F. Dekker,et al. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants , 2002, Thorax.
[42] R. Wood‐Baker,et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[43] R. Stockley,et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care , 2000, Thorax.
[44] R. Stockley,et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. , 2000, Chest.
[45] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[46] T. Seemungal,et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.
[47] R. Rodríguez-Roisín,et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. , 1998, American journal of respiratory and critical care medicine.
[48] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[49] J. Schwartz,et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. , 1997, The European respiratory journal.
[50] E. Vittinghoff,et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. , 1995, JAMA.